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Can Polymorphisms Predict
Response to Antiarrhythmic
Drugs in Atrial Fibrillation?*
James P. Daubert, MD,†
Geoffrey S. Pitt, MD, PHD‡
Durham, North Carolina
Ready or not, routine use of genetic information is immi-
nent in everyday cardiology practice. This impending reality
stems partly from the declining cost of whole-genome
sequencing that is now approaching the $1,000 barrier.
Clinicians undoubtedly could use such insight in managing
atrial fibrillation (AF), an extremely common and costly
condition. However, analyzing and applying the vast
amount of data housed in the human genome will clearly
present huge challenges. With this backdrop, Parvez et al.
(1) report in this issue of the Journal that response to certain
ntiarrhythmic drugs (AADs) may be genotype dependent.
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Using a single institution registry, the authors examined
success of AAD therapy in 676 Caucasian patients with AF.
Patients were included in the study if they had a docu-
mented history of AF with concurrent use of at least 1
conventional AAD (Vaughan-Williams class I or class III)
agent. About two-thirds had typical, but nonvalvular, AF—
that is, AF in conjunction with hypertension, coronary
artery disease, congestive heart failure, or diabetes—with
the remainder having lone AF. Response to therapy was
analyzed with a questionnaire (2) that yielded a symptom-
atic AF burden score by quantifying AF symptom fre-
quency, duration, and severity. A patient was deemed a
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from Medtronic.responder if she or he remained on the same AAD therapy
for a minimum of 6 months and had a 75% reduction in
their AF burden score. The investigators examined the
association between AAD responder status and the presence
of 4 single nucleotide polymorphisms (SNPs) that had
previously been linked with AF in genome-wide association
(GWA) studies.
Motivation for this study built from the recent recogni-
tion that family history is a risk factor for nonvalvular AF on
top of traditional risk factors, such as age, hypertension,
congestive heart failure, compromised respiratory function,
and hyperthyroidism. Like many complex polygenic disor-
ders, AF is inherited only rarely in Mendelian fashion, yet
having at least 1 parent with AF doubles the risk of AF (3).
For lone AF, family history confers an even greater risk (4).
everal GWA studies (5) have recently identified specific
enetic variants associated with AF, including 2 common
NPs on chromosome 4q25 (rs2200733 and rs10033464)
ear the transcription factor PITX2 (6). Subsequent studies
ave found a more definitive association for rs2200733 than
or rs10033464 (7–9). Two additional SNPs on chromo-
omes 1q21 and 16q22 with modest effects have also been
dentified (10,11).
With the rationale that the multiple genetic variants
ssociated with AF might indicate variable mechanisms
ontributing to AF susceptibility, or variable subtypes of
F, Parvez et al. (1) hypothesized that response to AAD
herapy might also be genotype dependent. Testing first in
discovery cohort of 478 patients, the authors identified an
ssociation between a response to AAD therapy and the
s10033464 SNP, but not with the other SNPs tested. The
ssociation with rs10033464 was predominantly, if not
xclusively, seen in patients with typical AF as opposed to
he patients with lone AF. Using multivariate regression,
he tendency to be a nonresponder to AAD therapy for
atients carrying a minor allele at rs10033464 persisted after
ontrolling for clinical variables such as age, sex, hyperten-
ion, coronary artery disease, heart failure, and diabetes.
nterestingly, the investigators further found that the re-
ponse rate to class I AADs was higher in patients with 1 or
ore minor alleles at rs10033464. On the other hand, the
esponse rate to class III AADs was higher in patients with
nly wild-type alleles. In a validation cohort of 178 Cauca-
ian patients with either lone or typical AF from Vanderbilt,
he association of rs10033464 with response to ADDs was
lso significant; subgroup analysis of typical versus lone AF
as not performed because of sample size.
Although this innovative study associating the SNP
s10033464 with AAD response breaks new ground, it
hould be considered hypothesis generating until confirmed
y a randomized, double-blinded trial. We share the au-
hors’ optimism that the genomic revolution will yield
pportunities to inform and tailor treatment, but this study
aises several questions. First, the AAD response rate of
2% to 83% is unusually high, even if amiodarone contrib-
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nonrigorous criteria for AAD success. Although freedom
from any AF may be too stringent and miss useful clinical
benefit of AAD (or ablation), success rates for AAD in a
recent randomized trial was only 16% (12). Even with a
more lenient endpoint in the AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) antiar-
rhythmic substudy, the 1-year success was only 23% for class
I AADs and only 38% for sotalol (13). Since AADs alone or
in combination with rate control agents may render AF less
symptomatic or even asymptomatic, the 75% reduction in
AF symptoms used to determine success in this study may
underestimate actual AF prevalence. The relative subjectivity
of the endpoint reduces confidence in the differences observed
for the rs10033464 SNP and for different AADs. Concerning
the secondary endpoint, AF recurrence, the intensity of mon-
itoring was less than that advocated by the Heart Rhythm
Society/European Heart Rhythm Association/European Car-
diac Arrhythmia Society Expert Consensus Statement on
Catheter and Surgical Ablation of AF, namely, a 24-h Holter
monitor every 3 to 6 months for 1 to 2 years (14).
A second weakness of the study is that the AAD selection
was not random, and the decision to continue it relatively
subjective, depending upon the patient’s and physician’s pref-
erences and the AF burden score. The patient-completed AF
symptom questionnaire may be dependent upon patient and
physician bias, and may not identify actual AF burden.
Third, the specific associations in this study are somewhat
at odds with findings from the large studies that first
identified these AF-related SNPs. The SNP highlighted in
this study, rs10033464, has been the polymorphism less
strongly associated with AF in GWA studies than its neighbor
on 4q25 (rs2200733). Since both SNPs are thought to involve
PITX2, the biological plausibility of the association is perhaps
weakened. It is curious also that rs10033464 was more clearly
associated with AAD response in typical AF patients in this
study, whereas SNPs at 4q25 had previously been more
strongly associated with lone AF (6).
Fourth, moving from statistical associations between
rs10033464 SNP status and AAD response, to using the
SNP information to guide therapy is problematic. For exam-
ple, the positive predictive value of minor allele carrier status for
predicting nonresponse to AAD is only 23%; that is, 25 of 109
total MAC patients in the discovery cohort were nonre-
sponders per Table 2 (1). Analogously, the differential response
to AADs is interesting and hypothesis generating, but difficult
to act on with the degree of differences found. Lastly, as with
any initial report, one needs to consider the possibility that the
associations arose by chance; such positive associations may be
more likely to be reported than negative ones (15).
In summary, Parvez et al. (1) are to be commended for
extending the epidemiological associations between several
SNPs and AF to an exploration of potential therapeutic
ramifications. Lacking patient-specific predictors for effi-
cacy, current AF drug selection considers only comorbidities
in an effort to merely minimize proarrhythmia (16). Phar-macogenetic insights could theoretically help predict efficacy
and toxicity. Although we are closer to the beginning than
to everyday use in the clinic, Parvez et al. (1) have started us
on an exciting journey.
Reprint requests and correspondence: Dr. James P. Daubert,
Box 3174, Duke University Medical Center, 2351 Erwin Road,
Durham, North Carolina 27710. E-mail: james.daubert@
duke.edu.
REFERENCES
1. Parvez B, Vaglio J, Rowan S, et al. Symptomatic response to
antiarrhythmic drug therapy is modulated by a common single nucle-
otide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012;60:
539–45.
2. Dorian P, Jung W, Newman D, et al. The impairment of health-
related quality of life in patients with intermittent atrial fibrillation:
implications for the assessment of investigational therapy. J Am Coll
Cardiol 2000;36:1303–9.
3. Fox CS, Parise H, D’Agostino RB Sr., et al. Parental atrial fibrillation
as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:
2851–5.
4. Arnar DO, Thorvaldsson S, Manolio TA, et al. Familial aggregation
of atrial fibrillation in Iceland. Eur Heart J 2006;27:708–12.
5. Lunetta KL. Genetic association studies. Circulation 2008;118:96–101.
6. Kaab S, Darbar D, van Noord C, et al. Large scale replication and
meta-analysis of variants on chromosome 4q25 associated with atrial
fibrillation. Eur Heart J 2009;30:813–9.
7. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring
risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:
353–7.
8. Lee KT, Yeh HY, Tung CP, et al. Association of RS2200733 but not
RS10033464 on 4q25 with atrial fibrillation based on the recessive
model in a Taiwanese population. Cardiology 2010;116:151–6.
9. Lubitz SA, Sinner MF, Lunetta KL, et al. Independent susceptibility
markers for atrial fibrillation on chromosome 4q25. Circulation 2010;
122:976–84.
10. Ellinor PT, Lunetta KL, Glazer NL, et al. Common variants in
KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010;
42:240–4.
11. Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant
in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic
stroke. Nat Genet 2009;41:876–8.
12. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic
drug therapy and radiofrequency catheter ablation in patients with
paroxysmal atrial fibrillation: a randomized controlled trial. JAMA
2010;303:333–40.
13. The AFFIRM First Antiarrhythmic Drug Substudy Investigators.
Maintenance of sinus rhythm in patients with atrial fibrillation: an
AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol
2003;42:20–9.
14. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert
consensus statement on catheter and surgical ablation of atrial fibril-
lation: recommendations for personnel, policy, procedures and follow-
up. A report of the Heart Rhythm Society (HRS) Task Force on
catheter and surgical ablation of atrial fibrillation. Heart Rhythm
2007;4:816–61.
15. Simes RJ. Publication bias: the case for an international registry of
clinical trials. J Clin Oncol 1986;4:1529–41.
16. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006
guidelines for the management of patients with atrial fibrillation: a
report of the American College of Cardiology/American Heart Asso-
ciation Task Force on Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines (Writing Committee
to Revise the 2001 Guidelines for the Management of Patients With
Atrial Fibrillation). J Am Coll Cardiol 2006;48:e149–246.
Key Words: antiarrhythmics y atrial fibrillation y genomics y
polymorphisms.
